Who are Azulfidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Silver Sulfadiazine, Azo Gantanol, Trimethoprim, Silvadene, Azo Gantrisin, Sulfamylon.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azulfidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Azulfidine — Competitive Intelligence Brief

Azulfidine (Sulfasalazine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonamide; aminosalicylate.

marketed Sulfonamide; aminosalicylate 5-aminosalicylic acid (5-ASA) moiety; connective tissue affinity Small molecule Live · refreshed every 30 min

Target snapshot

Azulfidine (Sulfasalazine) — Pfizer Inc.. Anti-inflammatory and immunomodulatory properties, with 5-ASA as major therapeutic moiety in ulcerative colitis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Azulfidine TARGET	Sulfasalazine	Pfizer Inc.	marketed	Sulfonamide; aminosalicylate	5-aminosalicylic acid (5-ASA) moiety; connective tissue affinity
Silver Sulfadiazine	SILVER	King Pharms Llc	marketed	Sulfonamide Antibacterial [EPC]		1990-01-01
Azo Gantanol	SULFAMETHOXAZOLE	Pfizer	marketed	Sulfonamide Antimicrobial [EPC]		1973-01-01
Trimethoprim	TRIMETHOPRIM	Dr Reddys Labs Sa	marketed	Sulfonamide Antimicrobial [EPC]	Dihydrofolate reductase	1973-01-01
Silvadene	Silver Sulfadiazine	Pfizer	marketed	sulfonamide antimicrobial	bacterial cell membrane and cell wall	1973-01-01
Azo Gantrisin	sulfafurazole	Alra	marketed	Sulfonamide Antimicrobial	Endothelin-1 receptor	1971-01-01
Sulfamylon	MAFENIDE	Rising	marketed	Methylated Sulfonamide Antibacterial	Carbonic anhydrase 12	1969-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonamide; aminosalicylate class)

Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azulfidine — Competitive Intelligence Brief. https://druglandscape.com/ci/azulfidine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab